<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2021.766464</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Definition of CRISPR Cas12a <italic>T</italic><italic>rans</italic>-Cleavage Units to Facilitate CRISPR Diagnostics</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Lv</surname> <given-names>Hailong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1299340/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Jian</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname> <given-names>Jian</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1481696/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname> <given-names>Yijian</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1473551/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Yin</surname> <given-names>Lei</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jin</surname> <given-names>Dian</given-names></name>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Gu</surname> <given-names>Dayong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhao</surname> <given-names>Huailong</given-names></name>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Xu</surname> <given-names>Yong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c003"><sup>&#x002A;</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname> <given-names>Jin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff8"><sup>8</sup></xref>
<xref ref-type="corresp" rid="c004"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/457147/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Clinical Laboratory, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People&#x2019;s Hospital</institution>, <addr-line>Shenzhen</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Biomedical Engineering, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Medicine, Shenzhen University</institution>, <addr-line>Shenzhen</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Institute of Antibiotics, Huashan Hospital, Fudan University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff>
<aff id="aff5"><sup>5</sup><institution>Tolo Biotechnology Company Limited</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff>
<aff id="aff6"><sup>6</sup><institution>TEDA Campus of Tianjin University of Science and Technology, Binhai New Area Development Zone</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff>
<aff id="aff7"><sup>7</sup><institution>Jinan Center for Disease Control and Prevention</institution>, <addr-line>Jinan</addr-line>, <country>China</country></aff>
<aff id="aff8"><sup>8</sup><institution>Guangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People&#x2019;s Hospital (Shenzhen Institute of Translational Medicine)</institution>, <addr-line>Shenzhen</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Guangcai Duan, Zhengzhou University, China</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Tao Liu, Huazhong Agricultural University, China; Haridha Shivram, Genentech, Inc., United States</p></fn>
<corresp id="c001">&#x002A;Correspondence: Dayong Gu, <email>wanhood@163.com</email></corresp>
<corresp id="c002">Huailong Zhao, <email>sdjlmu@163.cm</email></corresp>
<corresp id="c003">Yong Xu, <email>xuyong_2000@tom.com</email></corresp>
<corresp id="c004">Jin Wang, <email>wangj01@hotmail.com</email></corresp>
<fn fn-type="other" id="fn004"><p>This article was submitted to Evolutionary and Genomic Microbiology, a section of the journal Frontiers in Microbiology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>766464</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>08</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2021 Lv, Wang, Zhang, Chen, Yin, Jin, Gu, Zhao, Xu and Wang.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Lv, Wang, Zhang, Chen, Yin, Jin, Gu, Zhao, Xu and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>The CRISPR diagnostic (CRISPR-Dx) technology that employs the <italic>trans</italic>-cleavage activities has shown great potential in diagnostic sensitivity, specificity, convenience, and portability, and has been recognized as the next-generation diagnostic methods. However, due to the lack of standardized definition of Cas <italic>trans</italic>-cleavage enzymatic units, it is difficult to standardize the present CRISPR-Dx systems, which have undoubtedly impeded the development of the CRISPR-Dx industry. To solve the problem, we here first systematically optimized the reaction systems for Cas12a, and then defined its <italic>trans</italic>-cleavage units (<italic>trans</italic>U), which we believe will be of great importance and interest to researchers in both molecular diagnostic industry and basic research. Moreover, a simple protocol was provided to facilitate a step-by-step measurement of the Cas12a <italic>trans</italic>U, which can also act as a reference for the definition of the <italic>trans</italic>U for other Cas proteins.</p>
</abstract>
<kwd-group>
<kwd>CRISPR diagnostics</kwd>
<kwd><italic>trans</italic>-cleavage</kwd>
<kwd>enzymatic units</kwd>
<kwd>Cas12</kwd>
<kwd><italic>trans</italic>U</kwd>
</kwd-group>
<contract-num rid="cn001">31922046</contract-num>
<contract-num rid="cn001">31770057</contract-num>
<contract-num rid="cn002">SZSM202011017</contract-num>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content></contract-sponsor>
<contract-sponsor id="cn002">Sanming Project of Medicine in Shenzhen<named-content content-type="fundref-id">10.13039/501100012151</named-content></contract-sponsor>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="21"/>
<page-count count="8"/>
<word-count count="4777"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="S1">
<title>Introduction</title>
<p>The recently characterized <italic>trans</italic>-cleavage activities of the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas enzymes such as Cas12 and Cas13 has undoubtedly sparked the interests in developing CRISPR diagnostic (CRISPR-Dx) systems (<xref ref-type="bibr" rid="B8">Gootenberg et al., 2017</xref>, <xref ref-type="bibr" rid="B7">2018</xref>; <xref ref-type="bibr" rid="B2">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="B14">Li et al., 2018b</xref>; <xref ref-type="bibr" rid="B13">Li Y. et al., 2019</xref>). The <italic>trans</italic>-cleavage activities of Cas12a were first discovered during the characterization of its cleavage behaviors against target single-stranded DNA (ssDNA) (<xref ref-type="bibr" rid="B2">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="B15">Li et al., 2018a</xref>; <xref ref-type="bibr" rid="B13">Li Y. et al., 2019</xref>). Under the guidance of CRISPR RNA (crRNA), Cas12a recognizes target DNA, forms a ternary complex of Cas12a, crRNA, and target DNA, and then <italic>trans</italic>-cleaves non-specific ssDNA in the system, which activity is designated as the <italic>trans</italic>-cleavage activity (<xref ref-type="bibr" rid="B2">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="B15">Li et al., 2018a</xref>). Similar ssDNA <italic>trans</italic>-cleavage activities have been found in other Cas12 subtypes such as the thermophilic Cas12b and the Cas12f (previously known as Cas14) that specifically recognizes ssDNA targets (<xref ref-type="bibr" rid="B11">Leung et al., 2021</xref>). With the employment of these Cas12 <italic>trans</italic>-cleavage activities, dozens of CRISPR-Dx systems have been successfully created, among which HOLMES (one-hour low-cost multipurpose highly efficient system), HOLMESv2 and DETECTR (DNA Endonuclease Targeted CRISPR <italic>Trans</italic> Reporter) are the representatives (<xref ref-type="bibr" rid="B2">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="B14">Li et al., 2018b</xref>; <xref ref-type="bibr" rid="B12">Li L. et al., 2019</xref>).</p>
<p>HOLMES first uses the polymerase chain reaction (PCR) technology to amplify the target nucleic acids and then detects the amplicons with the Cas12a <italic>trans</italic>-cleavage activities, illuminating the fluorescent signals. HOLMES detects target nucleic acid sequences with the attomolar sensitivity and distinguishes single-base mismatches (<xref ref-type="bibr" rid="B14">Li et al., 2018b</xref>). However, the PCR amplification and Cas12a <italic>trans</italic>-cleavage processes are separated in HOLMES and the transfer of amplicons may result in aerosol contamination. To solve the problem, the physically separated amplification and Cas12a <italic>trans</italic>-cleavage steps may either be designed in a closed microfluidic system or operated in a standard PCR laboratory that contains separate rooms for distinct purposes; however, it may cause inconvenience in use of the HOLMES technology. Alternatively, HOLMESv2 integrates the thermophilic Cas12b with the Loop-mediated isothermal amplification (LAMP) and supports one-pot diagnosis of target nucleic acids (<xref ref-type="bibr" rid="B12">Li L. et al., 2019</xref>). Unlike Cas12, Cas13 targets RNA and is triggered to <italic>trans</italic>-cleave collateral single-stranded RNA reporter sequences in the system, with which diagnostic systems such as SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKing) (<xref ref-type="bibr" rid="B8">Gootenberg et al., 2017</xref>) were developed. Then, with the employment of Cas12 and Cas13, SHERLOCKv2 was created to simultaneously detect multiple target nucleic acids in one diagnostic system (<xref ref-type="bibr" rid="B7">Gootenberg et al., 2018</xref>). Recently, with the use of either tandem crRNAs or remarkably reduced reaction volumes for target nucleic acid detection, diagnostic sensitivities can be greatly improved, and several amplification-free systems have been successfully developed (<xref ref-type="bibr" rid="B6">Fozouni et al., 2021</xref>; <xref ref-type="bibr" rid="B16">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="B19">Shinoda et al., 2021</xref>; <xref ref-type="bibr" rid="B20">Tian et al., 2021</xref>; <xref ref-type="bibr" rid="B21">Yue et al., 2021</xref>).</p>
<p>In comparison with traditional molecular diagnostic methods such as polymerase chain reaction (PCR), CRISPR-Dx methods have shown great advantages in sensitivity, specificity, simplicity and portability and have been well recognized as the next-generation diagnostic methods (<xref ref-type="bibr" rid="B3">Chertow, 2018</xref>). Therefore, soon after the outbreak of the COVID-19 pandemic, a large number of diagnostic methods were successfully developed, most of which employed the immunochromatography and the real-time PCR technologies and have played an important role in the epidemic prevention and control. Meanwhile, dozens of CRISPR-Dx methods were also developed for COVID-19 diagnosis, including the one-pot systems that combine either recombinase polymerase amplification (RPA) with Cas12a (<xref ref-type="bibr" rid="B1">Aman et al., 2020</xref>; <xref ref-type="bibr" rid="B4">Ding et al., 2020</xref>) or LAMP with Cas12b (<xref ref-type="bibr" rid="B10">Joung et al., 2020</xref>), all showing advantages in diagnostic sensitivity, specificity, and convenience (<xref ref-type="bibr" rid="B9">Han et al., 2021</xref>). Noticeably, within 3 years since the first report of the CRISPR-Dx technology in 2017 (<xref ref-type="bibr" rid="B8">Gootenberg et al., 2017</xref>), the United States Food and Drug Administration (FDA) granted the Emergency Use Authorization (EUA) to Sherlock biosciences for the CRISPR SARS-CoV-2 rapid diagnostic kit (<xref ref-type="bibr" rid="B17">Martin et al., 2021</xref>), which once again confirmed the great potential of CRISPR technologies in pathogen diagnosis.</p>
<p>However, due to the lack of unified <italic>trans</italic>-cleavage units (<italic>trans</italic>U), the Cas enzymes used in present systems are usually quantitated in concentration instead of enzymatic units. As the Cas specific <italic>trans</italic>-cleavage activities may vary from different commercial providers, distinct diagnostic performances can be obtained for a defined CRISPR-Dx system if the Cas enzyme is definitized in concentration, which will undoubtedly limit large-scale industrial applications of CRISPR-Dx technologies. Besides, it is well known that enzymatic cleavage activities can be affected by many reaction factors, including ions, salt concentration, <italic>pH</italic> values and temperature. Therefore, we here systematically studied the factors affecting Cas12a <italic>trans</italic>-cleavage activities, optimized the reaction systems and finally defined its <italic>trans</italic>U. Moreover, a protocol was provided to simplify the <italic>trans</italic>U definition procedures.</p>
</sec>
<sec sec-type="results|discussion" id="S2">
<title>Results and Discussion</title>
<sec id="S2.SS1">
<title>Optimization of the Cas12a <italic>Trans</italic>-Cleavage Reporters</title>
<p>To precisely calculate the Cas12a <italic>trans</italic>-cleavage activity, the ssDNA reporter used was dual labeled with fluorophore and quencher (i.e., FQ-reporter), and the reaction was monitored by a fluorescence reader. To simplify the calculation, the <italic>trans</italic>-cleavage activity was calculated on the basis of the initial fluorescence growth rate <italic>v</italic><sub><italic>g</italic></sub> (<italic>v</italic><sub><italic>g</italic></sub> = &#x0394;F/&#x0394;t), following the recently published Michaelis-Menten model (<xref ref-type="bibr" rid="B18">Ramachandran and Santiago, 2021</xref>).</p>
<p>Non-paired ssDNA FQ-reporters are the substrates for Cas12a <italic>trans</italic>-cleavage reactions, and the sequences may affect the cleavage efficiencies (<xref ref-type="bibr" rid="B15">Li et al., 2018a</xref>). We first tested four homopolymers of 6 nucleotides in length, including poly-adenine (A), poly-cytosine (C), poly-guanine (G), and poly-thymine (T), respectively, and found Cas12a <italic>trans</italic>-cleaved the poly-C reporter with the highest efficiency but failed to cleave the poly-G reporter (<xref ref-type="fig" rid="F1">Figures 1A,B</xref>), which was consistent with the previous findings (<xref ref-type="bibr" rid="B21">Yue et al., 2021</xref>). Along with the elongation of the ssDNA reporter sequence, the <italic>v</italic><sub><italic>g</italic></sub> gradually increased and reached the peak when the sequence was longer than 8 nucleotides (<xref ref-type="fig" rid="F1">Figures 1C,D</xref>). Considering the fact that longer ssDNA FQ-reporter has higher background fluorescence and is more expensive to synthesize, the 8C FQ-reporter was chosen for the following assays.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>Optimization of the ssDNA reporter sequences. <bold>(A)</bold> Fluorescence curves of the Cas12a <italic>trans</italic>-cleavage reactions using different ssDNA reporter sequences. The reaction systems were comprised of 250 nM crRNA, 250 nM Cas12a, 3 nM target dsDNA, 1000 nM reporter and 1&#x00D7; NEBuffer 3.1. <bold>(B)</bold> Initial fluorescence growth rate of the reporters used in panel <bold>(A)</bold>. <bold>(C)</bold> Fluorescence curves of the Cas12a <italic>trans</italic>-cleavage reactions using poly-C ssDNA reporters of different lengths. The reaction systems were comprised of 250 nM crRNA, 250 nM Cas12a, 3 nM target dsDNA, 800 nM reporter, and 1&#x00D7; NEBuffer 3.1. <bold>(D)</bold> Initial fluorescence growth rate of the reporters used in panel <bold>(C)</bold>.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-12-766464-g001.tif"/>
</fig>
</sec>
<sec id="S2.SS2">
<title>Optimization of the Cas12a <italic>Trans</italic>-Cleavage Reaction Buffer</title>
<p>To optimize the Cas12a reaction buffer, we first compared several commercially available reaction buffers and found that Cas12a in buffer F had the highest <italic>trans</italic>-cleavage efficiencies (<xref ref-type="fig" rid="F2">Figure 2A</xref> and <xref ref-type="supplementary-material" rid="DS1">Supplementary Table 1</xref>). As the <italic>pH</italic> values may have influences on the Cas12a <italic>trans</italic>-cleavage activities, a group of commercially available standard buffers with <italic>pH</italic> values ranging from 3.5 to 9.6 in increments of 0.1 were further analyzed, through individually substituting the (hydroxymethyl)aminomethane (abbreviated as Tris) salt in buffer F. Among the tested conditions, Cas12a generally preferred buffers with high <italic>pH</italic> values and exhibited obviously higher <italic>trans</italic>-cleavage activities in the 1 M glycine buffer (<italic>pH</italic> 8.6) and the 1 M Tris&#x2013;HCl buffer (<italic>pH</italic> 8.5) (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Considering the buffering capacity in maintaining a stable <italic>pH</italic> value of the reaction buffers, especially when complicated samples are detected, the Tris&#x2013;HCl buffer (<italic>pH</italic> 8.5) was finally chosen. Meanwhile, the loss of Cas12a <italic>trans</italic>-cleavage activities in buffer C could be caused by either the relatively low <italic>pH</italic> value or the low concentration of Mg<sup>2+</sup>, which has been demonstrated to be important for the maintenance of Cas12a <italic>cis</italic>-cleavage activities in a previous study (<xref ref-type="bibr" rid="B5">Fonfara et al., 2016</xref>; <xref ref-type="supplementary-material" rid="DS1">Supplementary Table 1</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>Optimization of the Cas12a <italic>trans</italic>-cleavage reaction buffer. <bold>(A)</bold> Screening of the commercially available buffers. Detailed compositions of the tested buffers were listed in <xref ref-type="supplementary-material" rid="DS1">Supplementary Table 1</xref>. <bold>(B)</bold> Screening of the <italic>pH</italic> values with the <italic>pH</italic> slice plate (Cat. No. #HR2-070) from Hampton Research. The A&#x2013;H and 1&#x2013;12 indicated the positions in the 96-well plate and detailed components in each well were shown in <xref ref-type="supplementary-material" rid="DS1">Supplementary Sheet 1</xref>. Specifically, Cas12a in conditions of H5 (<italic>pH</italic> 8.6 in 1 M glycine buffer) and G2 (<italic>pH</italic> 8.5 in 1 M Tris&#x2013;HCl buffer) showed obviously higher <italic>trans</italic>-cleavage activities and the Tris buffer with <italic>pH</italic> 8.5 was finally chosen for further analysis. The <italic>trans</italic>-cleavage activities (RFU/min) were reflected by the colored histogram on the right side. <bold>(C)</bold> Screening of additives with the plate (Cat. No. #HR2-072) from Hampton Research. The A&#x2013;H and 1&#x2013;12 indicated the positions in the 96-well plate and detailed components in each well were shown in <xref ref-type="supplementary-material" rid="DS1">Supplementary Sheet 2</xref>. In comparison with the water control in A1, the Cas12a showed obviously higher <italic>trans</italic>-cleavage activities with several additives such as the G7 (glycerol), H5 (PEG 3,350), H6 (PEG 8,000), and H8 (PEG 20,000), and the most efficient H8 was employed for further analysis. The fold changes, relative to the activities in A1, were indicated by the colored histogram on the right side. <bold>(D)</bold> Comparison of the <italic>v</italic><sub><italic>g</italic></sub> of Cas12a in HOLMES Buffer 1 and NEB buffer 3.1.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-12-766464-g002.tif"/>
</fig>
<p>Meanwhile, dozens of additives were individually added into the reaction buffer F to test their efficacy on the Cas12a <italic>trans</italic>-cleavage activities, and several components such as polyethylene glycol (PEG) and glycerol obviously enhanced the cleavage signals and were chosen for further analysis (<xref ref-type="fig" rid="F2">Figure 2C</xref>). The chosen additives of different combinations and concentrations were compared and the condition of 0.4% PEG-20000 showed the most remarkable enhancement and was finally selected (<xref ref-type="supplementary-material" rid="DS1">Supplementary Figure 1</xref>). In addition, we found that non-ionic detergents such as Triton X-100 could also promoted the Cas12a <italic>trans</italic> activities.</p>
<p>After systematical analysis of the above selected components, an optimized reaction buffer namely HOLMES Buffer 1 showed better performance than buffer F in triggering the Cas12a <italic>trans</italic>-cleavage and was chosen for subsequent analysis (<xref ref-type="supplementary-material" rid="DS1">Supplementary Figure 2</xref> and section &#x201C;5.3.1&#x201D; in <xref ref-type="supplementary-material" rid="DS1">Supplementary Protocol</xref>). Moreover, through comparison with the control buffer of NEB buffer 3.1, HOLMES Buffer 1 remarkably enhanced the Cas12a <italic>trans</italic>-cleavage activities as well as its detection sensitivities (<xref ref-type="fig" rid="F2">Figure 2D</xref>).</p>
<p>Besides the reaction buffer, the ratio among Cas12a, crRNA, and target dsDNA could also be an important factor affecting the Cas12a <italic>trans</italic>-cleavage efficiencies, and different combinations were therefore tested in HOLMES Buffer 1. In theory, excessive amounts of crRNA and target dsDNA could promote the formation of the Cas12a ternary complex as well as triggering of the Cas12a <italic>trans</italic>-cleavage; however, we found that the Cas12a cleavage activity was slightly inhibited by high concentrations of crRNA and dsDNA with an unknown reason (<xref ref-type="supplementary-material" rid="DS1">Supplementary Figure 3</xref>). Therefore, a ratio of 1: 2: 2 was finally chosen to obtain the best kinetic parameters for Cas12a <italic>trans</italic>-cleavage in HOLMES Buffer 1.</p>
</sec>
<sec id="S2.SS3">
<title>Measurement of the Cas12a <italic>Trans</italic>-Cleavage Enzymatic Constants</title>
<p>At the presence of the target DNA, the Cas12a <italic>trans</italic>-cleaves the ssDNA FQ-reporter to illuminate fluorescent signals, which can be employed to measure the Cas12a enzymatic constants. However, as the fluorescence intensities may vary from different readers, standard curves should be first created to correlate the relative fluorescent units (RFUs) and the concentrations of the FQ-reporter, including both un-cleaved (i.e., the substrates) and the cleaved (i.e., the products) reporters (<xref ref-type="fig" rid="F3">Figures 3A,B</xref> and <xref ref-type="supplementary-material" rid="DS1">Supplementary Figures 4a,b</xref>). Briefly, the ssDNA FQ-reporter should be serially diluted and both cleaved and un-cleaved fluorescence signals are continually measured till the fluorescence reaches the saturation point, and the highest values of each gradient are then used for calibration of the standard curves for both cleaved and un-cleaved reporters (<xref ref-type="fig" rid="F3">Figures 3C,D</xref> and <xref ref-type="supplementary-material" rid="DS1">Supplementary Figures 4c,d</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>Correlation of the relative fluorescent units (RFUs) and the FQ-reporter concentration. <bold>(A)</bold> Fluorescence curves of the Cas12a <italic>trans</italic>-cleavage reactions using different ssDNA reporter concentration. <bold>(B)</bold> Fluorescence curves of the Cas12a <italic>trans</italic>-cleavage reactions using different ssDNA reporter concentration without target. The reaction systems were comprised of 40 nM crRNA, 20 nM Cas12a, 40 nM target dsDNA, and 1&#x00D7; HOLMES Buffer 1. <bold>(C)</bold> Background-subtracted fluorescence <italic>F</italic><sub><italic>cl</italic></sub> versus concentration of cleaved reporters. <bold>(D)</bold> Background-subtracted fluorescence <italic>F</italic><sub><italic>ucl</italic></sub> versus concentration of un-cleaved reporters. Solid lines are linear regression fits to experimental data (in symbols). Three replicates were measured for each concentration. Both cleaved and un-cleaved reporters were detected by the Applied Biosystems QuantStudio 3 machine.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-12-766464-g003.tif"/>
</fig>
<p>Then, with the employment of a limited concentration of Cas12a and crRNA and varied concentrations of ssDNA reporters, <italic>trans</italic>-cleavage enzymatic kinetics for Cas12a were determined, including the values of <italic>v</italic><sub>max</sub>, <italic>K</italic><sub>m</sub>, and <italic>K</italic><sub>cat</sub> (<xref ref-type="fig" rid="F4">Figure 4</xref> and <xref ref-type="supplementary-material" rid="DS1">Supplementary Table 2</xref>). Noticeably, the constants of <italic>K</italic><sub>m</sub>, <italic>K</italic><sub>cat</sub> as well as the <italic>K</italic><sub>cat</sub>/<italic>K</italic><sub>m</sub> were miscalculated in a previous study (<xref ref-type="bibr" rid="B2">Chen et al., 2018</xref>), which were much higher than the data in this study and another work (<xref ref-type="bibr" rid="B18">Ramachandran and Santiago, 2021</xref>) and have been recently corrected (<xref ref-type="supplementary-material" rid="DS1">Supplementary Table 3</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p>Analysis of the LbCas12a enzymatic kinetics. <bold>(A)</bold> Fluorescent curves of the Cas12a <italic>trans</italic>-cleavage reactions using different concentrations of the ssDNA reporter. <bold>(B)</bold> Analysis of the Michaelis-Menten constants of LbCas12a (Tolo Biotech.), employing 1 nM Cas12a and varied concentrations of ssDNA reporters.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-12-766464-g004.tif"/>
</fig>
</sec>
<sec id="S2.SS4">
<title>Definition of the Cas12a <italic>Trans</italic>-Cleavage Units</title>
<p>In the above-mentioned optimized reaction condition, the Cas12a <italic>trans</italic>-unit (<italic>trans</italic>U) was defined as the amount of Cas12a that <italic>trans</italic>-cleaves 1 pmol 8C FQ-reporter in 1 min at 37&#x00B0;C in a total reaction volume of 20 &#x03BC;L in HOLMES Buffer 1. To simplify the <italic>trans</italic>U measurement, a step-by-step protocol was provided in the <xref ref-type="supplementary-material" rid="DS1">Supplementary Protocol</xref>, which can be run on different fluorescence readers. Noticeably, as the Cas12a <italic>trans</italic>-cleavage efficiencies can be remarkably affected by the crRNA and target dsDNA sequences as well as their concentrations, the <italic>trans</italic>U should be determined using the same sequences and concentrations as provided in this study to unify the measurement (<italic>ref to</italic> sections &#x201C;5 and 6.2&#x201D; in <xref ref-type="supplementary-material" rid="DS1">Supplementary Protocol</xref>).</p>
<p>Briefly, a standard curve correlating the RFUs and the reporter concentrations should be drawn first, and then the <italic>trans</italic>-cleavage reaction is performed with serially diluted Cas12a and excess ssDNA reporters. The obtained data in the linear region are then used for calculation of the Cas12a <italic>trans</italic>U. Following this protocol, a commercially available LbCas12a was then analyzed, and the <italic>trans</italic>-cleavage activities were determined to be 51.65 <italic>trans</italic>Us/pmol (i.e., 19.36 fmol per <italic>trans</italic>U) (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p>Measurement of the LbCas12a specific <italic>trans</italic>-cleavage activities. <bold>(A)</bold> Fluorescent curves of the Cas12a <italic>trans</italic>-cleavage reactions with different concentrations of LbCas12a. LbCas12a was twofold serially diluted for the <italic>trans</italic>U measurement, using 1 &#x03BC;M ssDNA reporter as the substrate and following the <xref ref-type="supplementary-material" rid="DS1">Supplementary Protocol</xref>. <bold>(B)</bold> Curve plotting of calculated initial reaction rate <italic>versus</italic> the LbCas12a concentrations. The linear region of the reactions was boxed and enlarged, and the data were further employed for <italic>trans</italic>U calculation.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-12-766464-g005.tif"/>
</fig>
<p>Taken together, we here systematically optimized the Cas12a <italic>trans</italic>-cleavage reaction conditions, measured the Cas12a enzymatic constants and defined its <italic>trans</italic>U, which will undoubtedly facilitate the development and application of robust Cas12a-based CRISPR-Dx systems in the future. Moreover, following a similar approach, the <italic>trans</italic>U of other Cas effectors such as Cas12b, Cas12f, and Cas13 can be defined and their measurement protocols can be easily developed. On the other hand, although Cas12a exhibits much better performance in HOLMES Buffer 1 (e.g., with a higher <italic>K</italic><sub>cat</sub> value), one should be aware that there is still much work to do to further improve the Cas12a <italic>trans</italic>-cleavage activities, which may include the optimization of not only the reaction buffers but also the crRNA sequences in the future.</p>
</sec>
</sec>
<sec id="S3" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S3.SS1">
<title>Cas Proteins, Oligos, and Reagents</title>
<p>LbCas12a (LbCpf1) (Cat. No. #32108-03) was ordered from Tolo Biotech. (Shanghai, China). crRNAs were chemically synthesized by Biolino Acid Technology (Tianjin, China). FQ-labeled ssDNA reporters were ordered from Sangon Biotech. (Shanghai, China). The additive screening plates (Cat. No. #HR2-072) and the <italic>pH</italic> slice plate (Cat. No. #HR2-070) were ordered from Hampton Research (Aliso Viejo, CA).</p>
</sec>
<sec id="S3.SS2">
<title>Preparation of Target dsDNA</title>
<p>For the short dsDNA target, two complementary oligonucleotides were synthesized by commercial companies and then annealed to form dsDNA. Specifically, a pair of oligonucleotides (4 &#x03BC;M each) were mixed in 1&#x00D7; PCR buffer and then annealed in the following procedure with a thermal cycler: 95&#x00B0;C for 5 min and then reduced from 95 to 20&#x00B0;C at a rate of 1&#x00B0;C per minute. The annealed dsDNA target was diluted to 1 &#x03BC;M and stored at &#x2212;20&#x00B0;C before use.</p>
</sec>
<sec id="S3.SS3">
<title>Screening of the Cas12a <italic>Trans</italic>-Cleavage Additives</title>
<p>The Cas12a <italic>trans</italic>-cleavage reaction was performed in a 20-&#x03BC;L volume, following the conditions as described before (<xref ref-type="bibr" rid="B14">Li et al., 2018b</xref>). In detail, 50 nM crRNA, 5 nM Cas12a nuclease, 4 nM dsDNA target, and 200 nM 8C FQ-reporter were pre-mixed in 1&#x00D7; buffer F and then 16 &#x03BC;L of the mixture was aliquoted into the 96-well PCR plate, which should be operated on ice. Then, the reaction was initiated by adding 4-&#x03BC;L additives into each well and the fluorescence signals were measured by the qPCR machine (Applied Biosystems QuantStudio 3). The program was set at 37&#x00B0;C and signals (&#x03BB;ex: 488 nm; &#x03BB;em: 535 nm) were collected every 15 s. The initial fluorescence growth rate (<italic>v</italic><sub><italic>g</italic></sub>) was calculated according to the maximum slope of the fluorescence curve using the ICEKAT software<sup><xref ref-type="fn" rid="footnote1">1</xref></sup>.</p>
</sec>
<sec id="S3.SS4">
<title>Michaelis-Menten Analysis</title>
<p>The Michaelis-Menten was analyzed according to following equation: <italic>v</italic><sub>0</sub> = <italic>v</italic><sub>max</sub> [S]/(<italic>K</italic><sub>m</sub> + [S]), where [S] is the substrate concentration, <italic>v</italic><sub>max</sub> is the maximum reaction rate, and <italic>K</italic><sub>m</sub> is the Michaelis constant. The turnover number (<italic>K</italic><sub>cat</sub>) was determined by the equation: <italic>K</italic><sub>cat</sub> = <italic>v</italic><sub>max</sub>/[Et], where Et was the effective complex. The concentration of the activated Cas12a enzymatic complex was always kept at 1 nM in 1&#x00D7; reaction buffer. The Cas12a <italic>trans</italic>-cleavage reaction was initiated by the addition of the ssDNA FQ-reporter at the final concentrations of 0 nM, 3.9 nM, 7.8 nM, 15.6 nM, 31.2 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, and 1 &#x03BC;M, respectively. Reactions were carried out in three replicates at 37&#x00B0;C and fluorescence readouts were taken every 15 s. Background-subtracted fluorescence signals were obtained by subtracting the signal from a negative control. The <italic>v</italic><sub>0</sub> data were converted to nM/s from Relative Fluorescent Units using the calibrated standard curve (<italic>ref to</italic> section &#x201C;6.1&#x201D; in <xref ref-type="supplementary-material" rid="DS1">Supplementary Protocol</xref>), and the Michaelis-Menten constants were determined by plotting <italic>v</italic><sub>0</sub> against the substrate concentration and then fitting into the Michaelis-Menten curve (Graphpad Software).</p>
</sec>
</sec>
<sec sec-type="data-availability" id="S4">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="DS1">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="S5">
<title>Author Contributions</title>
<p>HL, JianW, and JZ performed most of the experiments. YC, LY, and DJ provided assistances in defining the Cas12a <italic>trans-</italic>cleavage units. HL and JinW drafted the manuscript. DG, HZ, YX, and JinW analyzed the data, revised the manuscript, and supervised the study. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>LY is employed by Tolo Biotechnology Company Limited, Shanghai, China. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="S6">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="S8">
<title>Funding</title>
<p>This work was supported by grants from the National Natural Science Foundation of China (31922046 and 31770057), Sanming Project of Medicine in Shenzhen (SZSM202011017), the National Key Research and Development Program of China (2018YFA0903700 and 2018YFC0809200), Guangdong Science and Technology Foundation (2020B1111160001, B2019228, and 2020A1515110744), and Shenzhen Science and Technology Foundation (SGLH20180625171602058, 201906133000069, GJHZ20200731095604013, and JCYJ20210324102803009). The sponsors have no involvement in the study design; collection, analysis, and interpretation of data; the writing of the manuscript, and the decision to submit the manuscript for publication.</p>
</sec>
<sec id="S7" sec-type="supplementary material"><title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmicb.2021.766464/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmicb.2021.766464/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.DOCX" id="DS1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_1.XLSX" id="TS1" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_2.XLSX" id="TS2" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aman</surname> <given-names>R.</given-names></name> <name><surname>Mahas</surname> <given-names>A.</given-names></name> <name><surname>Marsic</surname> <given-names>T.</given-names></name> <name><surname>Hassan</surname> <given-names>N.</given-names></name> <name><surname>Mahfouz</surname> <given-names>M. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Efficient, rapid, and sensitive detection of plant RNA viruses with one-pot RT-RPA-CRISPR/Cas12a assay.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>11</volume>:<issue>610872</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2020.610872</pub-id> <pub-id pub-id-type="pmid">33391239</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>J. S.</given-names></name> <name><surname>Ma</surname> <given-names>E.</given-names></name> <name><surname>Harrington</surname> <given-names>L. B.</given-names></name> <name><surname>Da Costa</surname> <given-names>M.</given-names></name> <name><surname>Tian</surname> <given-names>X.</given-names></name> <name><surname>Palefsky</surname> <given-names>J. M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity.</article-title> <source><italic>Science</italic></source> <volume>360</volume> <fpage>436</fpage>&#x2013;<lpage>439</lpage>.</citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chertow</surname> <given-names>D. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Next-generation diagnostics with CRISPR.</article-title> <source><italic>Science</italic></source> <volume>360</volume> <fpage>381</fpage>&#x2013;<lpage>382</lpage>.</citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname> <given-names>X.</given-names></name> <name><surname>Yin</surname> <given-names>K.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Lalla</surname> <given-names>R. V.</given-names></name> <name><surname>Ballesteros</surname> <given-names>E.</given-names></name> <name><surname>Sfeir</surname> <given-names>M. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay.</article-title> <source><italic>Nat. Commun.</italic></source> <volume>11</volume>:<issue>4711</issue>.</citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fonfara</surname> <given-names>I.</given-names></name> <name><surname>Richter</surname> <given-names>H.</given-names></name> <name><surname>Bratovic</surname> <given-names>M.</given-names></name> <name><surname>Le Rhun</surname> <given-names>A.</given-names></name> <name><surname>Charpentier</surname> <given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.</article-title> <source><italic>Nature</italic></source> <volume>532</volume> <fpage>517</fpage>&#x2013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1038/nature17945</pub-id> <pub-id pub-id-type="pmid">27096362</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fozouni</surname> <given-names>P.</given-names></name> <name><surname>Son</surname> <given-names>S.</given-names></name> <name><surname>Diaz De Leon Derby</surname> <given-names>M.</given-names></name> <name><surname>Knott</surname> <given-names>G. J.</given-names></name> <name><surname>Gray</surname> <given-names>C. N.</given-names></name> <name><surname>D&#x2019;ambrosio</surname> <given-names>M. V.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy.</article-title> <source><italic>Cell</italic></source> <volume>184</volume> <fpage>323.e329</fpage>&#x2013;<lpage>333.e329</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.12.001</pub-id> <pub-id pub-id-type="pmid">33306959</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gootenberg</surname> <given-names>J. S.</given-names></name> <name><surname>Abudayyeh</surname> <given-names>O. O.</given-names></name> <name><surname>Kellner</surname> <given-names>M. J.</given-names></name> <name><surname>Joung</surname> <given-names>J.</given-names></name> <name><surname>Collins</surname> <given-names>J. J.</given-names></name> <name><surname>Zhang</surname> <given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6.</article-title> <source><italic>Science</italic></source> <volume>360</volume> <fpage>439</fpage>&#x2013;<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaq0179</pub-id> <pub-id pub-id-type="pmid">29449508</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gootenberg</surname> <given-names>J. S.</given-names></name> <name><surname>Abudayyeh</surname> <given-names>O. O.</given-names></name> <name><surname>Lee</surname> <given-names>J. W.</given-names></name> <name><surname>Essletzbichler</surname> <given-names>P.</given-names></name> <name><surname>Dy</surname> <given-names>A. J.</given-names></name> <name><surname>Joung</surname> <given-names>J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Nucleic acid detection with CRISPR-Cas13a/C2c2.</article-title> <source><italic>Science</italic></source> <volume>356</volume> <fpage>438</fpage>&#x2013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1126/science.aam9321</pub-id> <pub-id pub-id-type="pmid">28408723</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>T.</given-names></name> <name><surname>Cong</surname> <given-names>H.</given-names></name> <name><surname>Shen</surname> <given-names>Y.</given-names></name> <name><surname>Yu</surname> <given-names>B.</given-names></name></person-group> (<year>2021</year>). <article-title>Recent advances in detection technologies for COVID-19.</article-title> <source><italic>Talanta</italic></source> <volume>233</volume>:<issue>122609</issue>.</citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joung</surname> <given-names>J.</given-names></name> <name><surname>Ladha</surname> <given-names>A.</given-names></name> <name><surname>Saito</surname> <given-names>M.</given-names></name> <name><surname>Kim</surname> <given-names>N. G.</given-names></name> <name><surname>Woolley</surname> <given-names>A. E.</given-names></name> <name><surname>Segel</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Detection of SARS-CoV-2 with SHERLOCK One-Pot testing.</article-title> <source><italic>N. Engl. J. Med.</italic></source> <volume>383</volume> <fpage>1492</fpage>&#x2013;<lpage>1494</lpage>.</citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname> <given-names>R. K.</given-names></name> <name><surname>Cheng</surname> <given-names>Q. X.</given-names></name> <name><surname>Wu</surname> <given-names>Z. L.</given-names></name> <name><surname>Khan</surname> <given-names>G.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Xia</surname> <given-names>H. Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>CRISPR-Cas12-based nucleic acids detection systems.</article-title> <source><italic>Methods [Online ahead of print]</italic></source> <pub-id pub-id-type="doi">10.1016/j.ymeth.2021.02.018</pub-id> <pub-id pub-id-type="pmid">33662563</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>L.</given-names></name> <name><surname>Li</surname> <given-names>S.</given-names></name> <name><surname>Wu</surname> <given-names>N.</given-names></name> <name><surname>Wu</surname> <given-names>J.</given-names></name> <name><surname>Wang</surname> <given-names>G.</given-names></name> <name><surname>Zhao</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>HOLMESv2: a CRISPR-Cas12b-assisted platform for nucleic acid detection and DNA methylation quantitation.</article-title> <source><italic>ACS Synth. Biol.</italic></source> <volume>8</volume> <fpage>2228</fpage>&#x2013;<lpage>2237</lpage>. <pub-id pub-id-type="doi">10.1021/acssynbio.9b00209</pub-id> <pub-id pub-id-type="pmid">31532637</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Li</surname> <given-names>S.</given-names></name> <name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>Liu</surname> <given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>CRISPR/Cas systems towards next-generation biosensing.</article-title> <source><italic>Trends Biotechnol.</italic></source> <volume>37</volume> <fpage>730</fpage>&#x2013;<lpage>743</lpage>.</citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>S. Y.</given-names></name> <name><surname>Cheng</surname> <given-names>Q. X.</given-names></name> <name><surname>Wang</surname> <given-names>J. M.</given-names></name> <name><surname>Li</surname> <given-names>X. Y.</given-names></name> <name><surname>Zhang</surname> <given-names>Z. L.</given-names></name> <name><surname>Gao</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2018b</year>). <article-title>CRISPR-Cas12a-assisted nucleic acid detection.</article-title> <source><italic>Cell Discov.</italic></source> <volume>4</volume>:<issue>20</issue>.</citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>S. Y.</given-names></name> <name><surname>Cheng</surname> <given-names>Q. X.</given-names></name> <name><surname>Liu</surname> <given-names>J. K.</given-names></name> <name><surname>Nie</surname> <given-names>X. Q.</given-names></name> <name><surname>Zhao</surname> <given-names>G. P.</given-names></name> <name><surname>Wang</surname> <given-names>J.</given-names></name></person-group> (<year>2018a</year>). <article-title>CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA.</article-title> <source><italic>Cell Res.</italic></source> <volume>28</volume> <fpage>491</fpage>&#x2013;<lpage>493</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-018-0022-x</pub-id> <pub-id pub-id-type="pmid">29531313</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>P. F.</given-names></name> <name><surname>Zhao</surname> <given-names>K. R.</given-names></name> <name><surname>Liu</surname> <given-names>Z. J.</given-names></name> <name><surname>Wang</surname> <given-names>L.</given-names></name> <name><surname>Ye</surname> <given-names>S. Y.</given-names></name> <name><surname>Liang</surname> <given-names>G. X.</given-names></name></person-group> (<year>2021</year>). <article-title>Cas12a-based electrochemiluminescence biosensor for target amplification-free DNA detection.</article-title> <source><italic>Biosens Bioelectron.</italic></source> <volume>176</volume>:<issue>112954</issue>. <pub-id pub-id-type="doi">10.1016/j.bios.2020.112954</pub-id> <pub-id pub-id-type="pmid">33412428</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>J.</given-names></name> <name><surname>Tena</surname> <given-names>N.</given-names></name> <name><surname>Asuero</surname> <given-names>A. G.</given-names></name></person-group> (<year>2021</year>). <article-title>Current state of diagnostic, screening and surveillance testing methods for COVID-19 from an analytical chemistry point of view.</article-title> <source><italic>Microchem. J.</italic></source> <volume>167</volume>:<issue>106305</issue>. <pub-id pub-id-type="doi">10.1016/j.microc.2021.106305</pub-id> <pub-id pub-id-type="pmid">33897053</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname> <given-names>A.</given-names></name> <name><surname>Santiago</surname> <given-names>J. G.</given-names></name></person-group> (<year>2021</year>). <article-title>CRISPR enzyme kinetics for molecular diagnostics.</article-title> <source><italic>Anal. Chem.</italic></source> <volume>93</volume> <fpage>7456</fpage>&#x2013;<lpage>7464</lpage>.</citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shinoda</surname> <given-names>H.</given-names></name> <name><surname>Taguchi</surname> <given-names>Y.</given-names></name> <name><surname>Nakagawa</surname> <given-names>R.</given-names></name> <name><surname>Makino</surname> <given-names>A.</given-names></name> <name><surname>Okazaki</surname> <given-names>S.</given-names></name> <name><surname>Nakano</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Amplification-free RNA detection with CRISPR-Cas13.</article-title> <source><italic>Commun. Biol.</italic></source> <volume>4</volume>:<issue>476</issue>.</citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>T.</given-names></name> <name><surname>Shu</surname> <given-names>B.</given-names></name> <name><surname>Jiang</surname> <given-names>Y.</given-names></name> <name><surname>Ye</surname> <given-names>M.</given-names></name> <name><surname>Liu</surname> <given-names>L.</given-names></name> <name><surname>Guo</surname> <given-names>Z.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>An ultralocalized Cas13a assay enables universal and nucleic acid amplification-free single-molecule RNA diagnostics.</article-title> <source><italic>ACS Nano</italic></source> <volume>15</volume> <fpage>1167</fpage>&#x2013;<lpage>1178</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c08165</pub-id> <pub-id pub-id-type="pmid">33498106</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname> <given-names>H.</given-names></name> <name><surname>Shu</surname> <given-names>B.</given-names></name> <name><surname>Tian</surname> <given-names>T.</given-names></name> <name><surname>Xiong</surname> <given-names>E.</given-names></name> <name><surname>Huang</surname> <given-names>M.</given-names></name> <name><surname>Zhu</surname> <given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Droplet Cas12a assay enables DNA quantification from unamplified samples at the single-molecule level.</article-title> <source><italic>Nano Lett</italic>.</source> <volume>21</volume> <fpage>4643</fpage>&#x2013;<lpage>4653</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.1c00715</pub-id> <pub-id pub-id-type="pmid">34038136</pub-id></citation></ref>
</ref-list>
<fn-group>
<fn id="footnote1">
<label>1</label>
<p><ext-link ext-link-type="uri" xlink:href="https://icekat.herokuapp.com/icekat">https://icekat.herokuapp.com/icekat</ext-link></p></fn>
</fn-group>
</back>
</article>
